Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
thiotepa · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| filgrastim | BIOLOGICAL | - |
| anastrozole | DRUG | - |
| carboplatin | DRUG | - |
| cisplatin | DRUG | - |
| cyclophosphamide | DRUG | - |
| etoposide | DRUG | - |
| thiotepa | DRUG | - |
| peripheral blood stem cell transplantation | PROCEDURE | - |
| radiation therapy | RADIATION | - |
DISEASE CHARACTERISTICS: Histologically confirmed epithelial carcinoma of the breast metastatic to any organ except brain, including ipsilateral supraclavicular (not axillary) lymph nodes and chest wall No apocrine, adenocystic, squamous cell carcinoma, sarcoma, or lymphoma Measurable or evaluable d...
Top 20 of 92 competitors
Thiotepa is an investigational small molecule being studied for the treatment of breast cancer, specifically in women with metastatic breast cancer. It is being evaluated as part of a chemotherapy regimen combined with peripheral stem cell transplantation. The drug is currently in Phase 2 clinical development for this indication.
Thiotepa is a small molecule therapeutic being studied in oncology. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being investigated for its role in treating metastatic breast cancer as part of a chemotherapy and stem cell transplant regimen.
Thiotepa is being developed by Meridian Bioscience Inc, a company listed on the stock exchange under the ticker VIVO. The company is conducting clinical research on this drug for the treatment of breast cancer.
Thiotepa is currently in Phase 2 clinical development for breast cancer. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy in patients.
Thiotepa has been studied in one completed clinical trial, identified as NCT00004900. This Phase 2 trial evaluated chemotherapy plus peripheral stem cell transplantation in treating women with metastatic breast cancer. The trial was conducted in the United States and enrolled female patients aged 18 years and older.
Thiotepa is a distinct drug entity being developed by Meridian Bioscience Inc. No alternative names for this drug have been reported in the available clinical trial information. It is being studied specifically for its potential role in treating metastatic breast cancer.